More News

21 Mar 2018 Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
20 Mar 2018 Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies
19 Mar 2018 Mundipharma expands biosimilar portfolio with exclusive partnership deal across seven European countries for trastuzumab biosimilar, Herzuma®
16 Mar 2018 Bavarian Nordic Announces Partnership with U.S. Department of Defense to Combat Equine Encephalitis Virus
16 Mar 2018 Lundbeck to acquire Prexton Therapeutics in a deal valued at up to €905 million
16 Mar 2018 Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer
15 Mar 2018 Ionis and Akcea Partner to Commercialize Inotersen for hATTR
15 Mar 2018 Crinetics Pharmaceuticals Completes $63.5 Million Series B Financing
14 Mar 2018 Escalier Biosciences Raises $19 Million to Develop its Topical and Systemic RORγt Therapies for Psoriasis and other Autoimmune Diseases
14 Mar 2018 AveXis Enters into Licensing Agreement with Genethon
12 Mar 2018 Biogen to Acquire from Pfizer First-in-Class Phase 2b Ready Asset for Cognitive Impairment Associated with Schizophrenia
08 Mar 2018 Zydus partners with Medicure to launch its NDA Product, ZYPITAMAG (pitavastatin) in the U.S.
07 Mar 2018 MD Anderson and Berkeley Lights Launch Optera Therapeutics to Accelerate Development of Cell Therapies for Cancer
07 Mar 2018 Aptose Biosciences Announces Exclusive License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology
07 Mar 2018 CEPI Partners with Themis Bioscience to Advance Vaccines Against Lassa Fever and MERS
07 Mar 2018 Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences
06 Mar 2018 Caladrius Biosciences Acquires an Exclusive License to a Late Stage CD34+ Cell Therapy Program for the Treatment of Refractory Angina
06 Mar 2018 Vividion Therapeutics Announces Strategic Research Collaboration with Celgene Corporation to Discover Therapies Against Transformative, First-in-Class Targets
06 Mar 2018 Magenta Therapeutics and Heidelberg Pharma Sign Exclusive Multi-Target Research Agreement for the Development of Antibody Drug Conjugates
01 Mar 2018 C3J Therapeutics Bolsters Antimicrobial R&D Program; Acquires Engineered Bacteriophage Assets from Synthetic Genomics
01 Mar 2018 Heidelberg Pharma Signs License Agreement with The University of Texas MD Anderson Cancer Center
01 Mar 2018 Mylan to Bring a Biosimilar of BOTOX to the Market Through a Collaboration and License agreement with Revance Therapeutics
28 Feb 2018 Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis
28 Feb 2018 MedImmune to create stand-alone company for early-stage inflammation and autoimmunity biologics
27 Feb 2018 Aldeyra Therapeutics Announces Agreement with Johnson & Johnson Innovation to Advance Novel Immune-Modulating Drugs for Systemic Inflammatory Diseases

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up